11/30/2021 | Press release | Distributed by Public on 11/30/2021 16:12
| | | ||||||||||||
| | | | | | | | | | |||||
| | | |
Per share
|
| |
Total
|
| ||||||
|
Public offering price
|
| | | $ | | | | | $ | | | ||
|
Underwriting discounts and commissions(1)
|
| | | $ | | | | | $ | | | ||
|
Proceeds to ImmunoGen, before expenses
|
| | | $ | | | | | $ | | | ||
| | | | | | | | | | | | | | |
| Jefferies | | |
Cowen
|
| |
Guggenheim Securities
|
|
| | ||||||
| | ||||||
TABLE OF CONTENTS | | | |||||
ABOUT THIS PROSPECTUS SUPPLEMENT
|
| | | | S-i | | |
PROSPECTUS SUPPLEMENT SUMMARY
|
| | | | S-1 | | |
THE OFFERING
|
| | | | S-4 | | |
RISK FACTORS
|
| | | | S-5 | | |
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
|
| | | | S-10 | | |
USE OF PROCEEDS
|
| | | | S-11 | | |
DILUTION
|
| | | | S-12 | | |
UNDERWRITING
|
| | | | S-14 | | |
LEGAL MATTERS
|
| | | | S-22 | | |
EXPERTS
|
| | | | S-22 | | |
WHERE YOU CAN FIND MORE INFORMATION
|
| | | | S-23 | | |
INCORPORATION OF DOCUMENTS BY REFERENCE
|
| | | | S-23 | | |
| |
| | ||||||||||||
| | | | ||||||||||
Public offering price per share
|
| | | | | | | | | $ | | | |
Net tangible book value per share as of September 30, 2021
|
| | | $ | 0.38 | | | | | | | | |
Increase in net tangible book value per share attributable to new investors purchasing shares in this offering
|
| | | | | | | | | | | | |
As adjusted net tangible book value per share as of September 30, 2021 after this offering
|
| | | | | | | | | | | | |
Dilution per share to new investors purchasing shares in this offering
|
| | | | | | | | | $ | | | |
| |
| | |||
Underwriter
|
| |
Number
of Shares |
|
Jefferies LLC
|
| | | |
Cowen and Company, LLC
|
| | | |
Guggenheim Securities, LLC
|
| | | |
Canaccord Genuity, LLC
|
| | | |
Total: | | | | |
| |
| | ||||||||||||||||||
| | ||||||||||||||||||
| | |
Per
share |
| |
Without
exercise of option to purchase additional shares |
| |
With full
exercise of option to purchase additional shares |
| |||||||||
Public offering price
|
| | | $ | | | | | $ | | | | | $ | | | |||
Underwriting discounts and commissions paid by us
|
| | | $ | | | | | $ | | | | | $ | | | |||
Proceeds to us, before expenses
|
| | | $ | | | | | $ | | | | | $ | | | |||
| |
| | |
Page
|
| |||
ABOUT THIS PROSPECTUS
|
| | | | 1 | | |
PROSPECTUS SUMMARY
|
| | | | 2 | | |
RISK FACTORS
|
| | | | 5 | | |
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
|
| | | | 5 | | |
USE OF PROCEEDS
|
| | | | 6 | | |
DESCRIPTION OF COMMON STOCK
|
| | | | 6 | | |
DESCRIPTION OF PREFERRED STOCK
|
| | | | 6 | | |
DESCRIPTION OF DEBT SECURITIES
|
| | | | 7 | | |
DESCRIPTION OF WARRANTS
|
| | | | 13 | | |
DESCRIPTION OF UNITS
|
| | | | 14 | | |
SELLING SECURITYHOLDERS
|
| | | | 14 | | |
CERTAIN PROVISIONS OF MASSACHUSETTS LAW AND OF THE COMPANY'S ARTICLES OF ORGANIZATION AND BY-LAWS
|
| | | | 14 | | |
LEGAL MATTERS
|
| | | | 16 | | |
EXPERTS
|
| | | | 16 | | |
WHERE YOU CAN FIND MORE INFORMATION
|
| | | | 16 | | |
INCORPORATION OF DOCUMENTS BY REFERENCE
|
| | | | 16 | | |